-transparent.png){kind=logo}
BACKGROUND Herpes simplex thymidine kinase (HTK) is known to phosphorylate ganciclovir (GCV). Phosphorylated GCV is incorporated into genomic DNA, which leads to inhibition of cell growth and cell death in the replicating cells. Recently, much attention has been drawn to the use of retrovirally mediated gene therapy using HTK as a new therapeutic approach for brain tumors. However, little is known about this phenomenon in gastrointestinal carcinomas. METHODS The authors transfected the HTK gene packaged in retroviral vector into TMK-1 gastric carcinoma cells (TMK-HTK cells). Sensitivity of TMK-HTK cells to GCV was examined in vitro. Moreover, TMK-HTK cells were transduced into nude mice subcutaneously, and the effects of GCV therapy was examined at the concentration of 20 mg/kg daily for 14 days. RESULTS TMK-HTK cells were sensitive to GCV at the concentration of 0.1 to 100 micrograms/ml in a dose- and time-dependent manner in vitro. Moreover, 12 of 13 TMK-HTK tumors, which were transduced into nude mice subcutaneously, shrunk from the average diameter of 6.5 mm. CONCLUSIONS The results indicate that retrovirally transmitted gene therapy with GCV may provide a new therapeutic approach for treatment of gastric carcinomas.
K Yoshida, and
H Kawami, and
Y Yamaguchi, and
H Kuniyasu, and
M Nishiyama, and
T Hirai, and
K Yanagihara, and
E Tahara, and
T Toge
September 1999,
Cell research,
K Yoshida, and
H Kawami, and
Y Yamaguchi, and
H Kuniyasu, and
M Nishiyama, and
T Hirai, and
K Yanagihara, and
E Tahara, and
T Toge
March 2000,
Gynecologic oncology,
K Yoshida, and
H Kawami, and
Y Yamaguchi, and
H Kuniyasu, and
M Nishiyama, and
T Hirai, and
K Yanagihara, and
E Tahara, and
T Toge
January 1999,
Gynecologic oncology,
K Yoshida, and
H Kawami, and
Y Yamaguchi, and
H Kuniyasu, and
M Nishiyama, and
T Hirai, and
K Yanagihara, and
E Tahara, and
T Toge
January 1996,
Human gene therapy,
K Yoshida, and
H Kawami, and
Y Yamaguchi, and
H Kuniyasu, and
M Nishiyama, and
T Hirai, and
K Yanagihara, and
E Tahara, and
T Toge
February 2004,
Journal of hepatology,
K Yoshida, and
H Kawami, and
Y Yamaguchi, and
H Kuniyasu, and
M Nishiyama, and
T Hirai, and
K Yanagihara, and
E Tahara, and
T Toge
January 1976,
Bulletin du cancer,
K Yoshida, and
H Kawami, and
Y Yamaguchi, and
H Kuniyasu, and
M Nishiyama, and
T Hirai, and
K Yanagihara, and
E Tahara, and
T Toge
March 2008,
Cancer letters,
K Yoshida, and
H Kawami, and
Y Yamaguchi, and
H Kuniyasu, and
M Nishiyama, and
T Hirai, and
K Yanagihara, and
E Tahara, and
T Toge
June 1999,
International journal of oncology,
K Yoshida, and
H Kawami, and
Y Yamaguchi, and
H Kuniyasu, and
M Nishiyama, and
T Hirai, and
K Yanagihara, and
E Tahara, and
T Toge
February 2001,
Cancer gene therapy,
K Yoshida, and
H Kawami, and
Y Yamaguchi, and
H Kuniyasu, and
M Nishiyama, and
T Hirai, and
K Yanagihara, and
E Tahara, and
T Toge
January 2003,
European journal of endocrinology,
